108 related articles for article (PubMed ID: 23732371)
1. Intraorbital injection of rituximab: a new approach for active thyroid-associated orbitopathy, a prospective case series.
Savino G; Balia L; Colucci D; Battendieri R; Gari M; Corsello SM; Pontecorvi A; Dickmann A
Minerva Endocrinol; 2013 Jun; 38(2):173-9. PubMed ID: 23732371
[TBL] [Abstract][Full Text] [Related]
2. Intraorbital injection of rituximab versus high dose of systemic glucocorticoids in the treatment of thyroid-associated orbitopathy.
Savino G; Mandarà E; Gari M; Battendieri R; Corsello SM; Pontecorvi A
Endocrine; 2015 Feb; 48(1):241-7. PubMed ID: 24880619
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
Salvi M; Vannucchi G; Campi I; Currò N; Dazzi D; Simonetta S; Bonara P; Rossi S; Sina C; Guastella C; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2007 Jan; 156(1):33-40. PubMed ID: 17218723
[TBL] [Abstract][Full Text] [Related]
4. New immunomodulators in the treatment of Graves' ophthalmopathy.
Salvi M; Vannucchi G; Campi I; Currò N; Beck-Peccoz P
Ann Endocrinol (Paris); 2008 Apr; 69(2):153-6. PubMed ID: 18417090
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression.
Salvi M; Vannucchi G; Campi I; Rossi S; Bonara P; Sbrozzi F; Guastella C; Avignone S; Pirola G; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2006 Apr; 154(4):511-7. PubMed ID: 16556712
[TBL] [Abstract][Full Text] [Related]
6. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy.
Khanna D; Chong KK; Afifiyan NF; Hwang CJ; Lee DK; Garneau HC; Goldberg RA; Darwin CH; Smith TJ; Douglas RS
Ophthalmology; 2010 Jan; 117(1):133-139.e2. PubMed ID: 19818507
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.
Salvi M; Vannucchi G; Currò N; Campi I; Covelli D; Dazzi D; Simonetta S; Guastella C; Pignataro L; Avignone S; Beck-Peccoz P
J Clin Endocrinol Metab; 2015 Feb; 100(2):422-31. PubMed ID: 25494967
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in the treatment of thyroid eye disease: science fiction?
Salvi M; Vannucchi G; Campi I; Beck-Peccoz P
Orbit; 2009; 28(4):251-5. PubMed ID: 19839884
[TBL] [Abstract][Full Text] [Related]
9. Rapid response to and long-term effectiveness of anti-CD20 antibody in conventional therapy resistant Graves' orbitopathy: A five-year follow-up study.
Erdei A; Paragh G; Kovacs P; Karanyi Z; Berenyi E; Galuska L; Lenkey A; Szabados L; Gyory F; Ujhelyi B; Berta A; Boda J; Berta E; Bodor M; Gazdag A; Nagy EV
Autoimmunity; 2014 Dec; 47(8):548-55. PubMed ID: 25039242
[TBL] [Abstract][Full Text] [Related]
10. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy.
Bonara P; Vannucchi G; Campi I; Rossi S; Cantoni F; Frugoni C; Sbrozzi F; Guastella C; Avignone S; Beck-Peccoz P; Salvi M
Clin Rev Allergy Immunol; 2008 Feb; 34(1):118-23. PubMed ID: 18270865
[TBL] [Abstract][Full Text] [Related]
11. Potential utility of rituximab for Graves' orbitopathy.
Salvi M; Vannucchi G; Beck-Peccoz P
J Clin Endocrinol Metab; 2013 Nov; 98(11):4291-9. PubMed ID: 24009135
[TBL] [Abstract][Full Text] [Related]
12. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates.
Salvi M; Vannucchi G; Campi I; Currò N; Simonetta S; Covelli D; Pignataro L; Guastella C; Rossi S; Bonara P; Dazzi D; Ratiglia R; Beck-Peccoz P
Clin Immunol; 2009 May; 131(2):360-5. PubMed ID: 19195932
[TBL] [Abstract][Full Text] [Related]
13. The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves' orbitopathy.
Mitchell AL; Gan EH; Morris M; Johnson K; Neoh C; Dickinson AJ; Perros P; Pearce SH
Clin Endocrinol (Oxf); 2013 Sep; 79(3):437-42. PubMed ID: 23320840
[TBL] [Abstract][Full Text] [Related]
14. Treatment of thyroid-associated orbitopathy with rituximab--a novel therapy for an old disease: case report and literature review.
Madaschi S; Rossini A; Formenti I; Lampasona V; Marzoli SB; Cammarata G; Politi LS; Martinelli V; Bazzigaluppi E; Scavini M; Bosi E; Lanzi R
Endocr Pract; 2010; 16(4):677-85. PubMed ID: 20350915
[TBL] [Abstract][Full Text] [Related]
15. Rituximab (Rituxan) therapy for severe thyroid-associated ophthalmopathy diminishes IGF-1R(+) T cells.
McCoy AN; Kim DS; Gillespie EF; Atkins SJ; Smith TJ; Douglas RS
J Clin Endocrinol Metab; 2014 Jul; 99(7):E1294-9. PubMed ID: 24670080
[TBL] [Abstract][Full Text] [Related]
16. [New immunomodulators in treatment of Graves'ophtalmopathy].
Josseaume C; Lorcy Y
Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S29-32. PubMed ID: 18954856
[TBL] [Abstract][Full Text] [Related]
17. Randomized controlled trial of rituximab in patients with Graves' orbitopathy.
Stan MN; Garrity JA; Carranza Leon BG; Prabin T; Bradley EA; Bahn RS
J Clin Endocrinol Metab; 2015 Feb; 100(2):432-41. PubMed ID: 25343233
[TBL] [Abstract][Full Text] [Related]
18. [Anti-cytokine and anti-lymphocyte monoclonal antibodies in the treatment of thyroid associated ophthalmopathy].
Komorowski J; Jankiewicz-Wika J; Siejka A; Lawnicka H; Stepień H
Pol Merkur Lekarski; 2007 Jun; 22(132):571-4. PubMed ID: 17874632
[TBL] [Abstract][Full Text] [Related]
19. B-cell targeted therapy with rituximab for thyroid eye disease: closer to the clinic.
Shen S; Chan A; Sfikakis PP; Hsiu Ling AL; Detorakis ET; Boboridis KG; Mavrikakis I
Surv Ophthalmol; 2013; 58(3):252-65. PubMed ID: 23253433
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for thyroid eye disease.
Oh SR; Priel A; Levi L; Granet DB; Korn BS; Kikkawa DO
Ophthalmology; 2011 Apr; 118(4):792; author reply 792-3. PubMed ID: 21459230
[No Abstract] [Full Text] [Related]
[Next] [New Search]
